Use of Continuous Glucose Monitoring in Older Adults: A Review of Benefits, Challenges and Future Directions.
Diabetes
blood glucose monitoring
continuous glucose monitoring
diabetes management
diabetes technology
older adults
Journal
TouchREVIEWS in endocrinology
ISSN: 2752-5457
Titre abrégé: touchREV Endocrinol
Pays: England
ID NLM: 101779126
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
01
09
2022
accepted:
24
10
2022
entrez:
25
1
2023
pubmed:
26
1
2023
medline:
26
1
2023
Statut:
ppublish
Résumé
Many new technologies have been developed over the past decade, and these have substantially changed the way diabetes is managed. Continuous glucose monitoring is now the standard of care for many people living with diabetes, and among its numerous benefits, it has been shown to improve glycaemic outcomes and enhance quality of life. Older adults carry a high burden of diabetes and have a high risk of hypo-glycaemia and hypo-glycaemic unawareness, and continuous glucose monitoring can help to improve glycaemic management in this vulnerable population. Unfortunately, only a few trials have evaluated the effectiveness of continuous glucose monitoring in older adults. Certainly, the implementation of continuous glucose monitoring in older adults can come with many challenges, including logistical, educational and reimbursement barriers. This article will discuss the benefits of continuous glucose monitoring in older adults with diabetes, the clinical studies that support its use and the barriers to its optimal implementation in this population.
Identifiants
pubmed: 36694891
doi: 10.17925/EE.2022.18.2.116
pmc: PMC9835808
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
116-121Informations de copyright
© Touch Medical Media 2022.
Références
JAMA. 2021 Jun 8;325(22):2262-2272
pubmed: 34077499
Diabetes Educ. 2020 Aug;46(4):315-322
pubmed: 32780001
Diabetes Technol Ther. 2022 May;24(5):299-306
pubmed: 34939824
Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S3-S13
pubmed: 26784127
J Diabetes Sci Technol. 2017 Nov;11(6):1138-1146
pubmed: 28449590
Ann Intern Med. 2017 Sep 19;167(6):365-374
pubmed: 28828487
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96
pubmed: 34964868
Diabetes Care. 2016 Apr;39(4):603-10
pubmed: 26681721
BMJ Open. 2019 Nov 18;9(11):e032037
pubmed: 31740472
J Diabetes Sci Technol. 2016 Jun 28;10(4):892-7
pubmed: 27022095
Diabetes Care. 2017 Dec;40(12):1651-1660
pubmed: 28716781
J Diabetes Complications. 2018 Aug;32(8):805-812
pubmed: 29887300
JAMA Intern Med. 2014 Jul;174(7):1116-24
pubmed: 24838229
Endocrinol Metab Clin North Am. 2020 Mar;49(1):57-67
pubmed: 31980121
Diabetes Technol Ther. 2022 Jun;24(6):424-434
pubmed: 35294272
Diabetes Care. 2022 Jan 1;45(Suppl 1):S195-S207
pubmed: 34964847
Endocr Pract. 2021 Jun;27(6):505-537
pubmed: 34116789
Lancet. 2018 Apr 7;391(10128):1367-1377
pubmed: 29459019
JAMA. 2017 Jan 24;317(4):371-378
pubmed: 28118453
Diabetes Care. 2022 Jan 1;45(Suppl 1):S97-S112
pubmed: 34964871
JMIR Diabetes. 2022 Mar 16;7(1):e35687
pubmed: 35293868
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
Diabetes Care. 2019 Jul;42(7):1178-1184
pubmed: 31036546
JAMA. 2009 Apr 15;301(15):1565-72
pubmed: 19366776
Aging Dis. 2015 Mar 10;6(2):156-67
pubmed: 25821643
Pilot Feasibility Stud. 2021 Jan 6;7(1):12
pubmed: 33407924
JAMA. 2017 Jan 24;317(4):379-387
pubmed: 28118454
JAMA. 2020 Jun 16;323(23):2397-2406
pubmed: 32543682
Diabetes Technol Ther. 2019 Oct;21(10):566-574
pubmed: 31335199
World J Diabetes. 2015 Jul 10;6(7):912-26
pubmed: 26185599